Fig. 3From: Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapyPredictive versus prognostic values of the CD8xPD-L1 signature. These are demonstrated by Kaplan-Meier analysis of overall survival for the CD8xPD-L1 signature in the combined (training and test) set of patients treated with durvalumab (a) compared to the set of non-immune checkpoint therapy (ICT) patients (b). Kaplan-Meier curves show survival probability, with shaded areas representing 95% confidence intervals. The prevalence for the non-ICT patients was matched to that for patients treated with durvalumab. The resulting cutoffs for CD8xPD-L1 signature positivity for the durvalumab and non-ICT sets respectively were 1.54 × 105 and 2.85 × 104 cells2/mm4Back to article page